Enliven Therapeutics, Inc. $ELVN Shares Bought by Tema ETFs LLC

Tema ETFs LLC grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 41.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 60,694 shares of the company’s stock after purchasing an additional 17,638 shares during the period. Tema ETFs LLC’s holdings in Enliven Therapeutics were worth $3,080,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. KBC Group NV purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. grew its position in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares during the period. BNP Paribas Financial Markets grew its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the period. Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics in the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP increased its holdings in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Performance

ELVN stock opened at $57.92 on Thursday. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $62.32. The stock’s 50 day moving average price is $49.97 and its 200 day moving average price is $40.44. The firm has a market cap of $4.24 billion, a P/E ratio of -34.68 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on ELVN shares. The Goldman Sachs Group boosted their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. HC Wainwright raised their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Guggenheim decreased their target price on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, JonesTrading raised their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $72.67.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the sale, the chief financial officer owned 46,054 shares of the company’s stock, valued at $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 190,831 shares of company stock valued at $10,991,723 over the last quarter. Insiders own 3.00% of the company’s stock.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.